Development of a reverse genetics system for respiratory syncytial virus long strain and an immunogenicity study of the recombinant virus

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Hu, Bing ^a   Jiang, Jiawei ^a   Zhan, Jianbo ^a   Li, Guoming ^a   Jiang, Yongzhong ^a   Guan, Xuhua ^a   Chen, Yuanding ^b   Fang, Zhizheng ^c  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b INSTITUTE OF MEDICAL BIOLOGY   (China)

^c Wuhan Institute of Biological Products China Pharmaceutical Group Corporation   (China)

Author keywords

Attenuated vaccine candidates; Immunogenicity; Protection; Respiratory syncytial virus (RSV) Long strain; Reverse genetics

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; NEUTRALIZING ANTIBODY; IMMUNOGLOBULIN G; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; AUTOFLUORESCENCE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; HEP 2 CELL LINE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LUNG PARENCHYMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVERSE GENETICS; VIRAL CLEARANCE; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS STRAIN; VIRUS VIRULENCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; GENE VECTOR; GENETIC ENGINEERING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPG2 CELL LINE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; PROCEDURES; REPORTER GENE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; T LYMPHOCYTE SUBPOPULATION; VIRAL PLAQUE ASSAY; VIROLOGY; VIRUS REPLICATION;

RESPIRATORY SYNCYTIAL VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENES, REPORTER; GENETIC ENGINEERING; GENETIC VECTORS; HEP G2 CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; REVERSE GENETICS; T-LYMPHOCYTE SUBSETS; VIRAL PLAQUE ASSAY; VIRUS REPLICATION;

EID: 84906922990     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-11-142     Document Type: Article

References (42)

1. RSV infection course in infants and young children during hospitalization. Chrobak E, Machura E, Wrzask M, Krakowczyk H, Mielczarek M, Przegl Lek 2011 68 63 67
2. Respiratory syncytial virus infection in elderly and high-risk adults. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE, N Engl J Med 2005 352 1749 1759
3. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Castilow EM, Olson MR, Varga SM, Immunol Res 2007 39 225 239
4. Whole genome characterization of non-tissue culture adapted HRSV strains in severely infected children. Kumaria R, Iyer LR, Hibberd ML, Simões EA, Sugrue RJ, Virol J 2011 8 372
5. Human respiratory syncytial virus strain ATCC VR-26, complete genome 2009. Lo MS, Brazas RM, Holtzman MJ, http://www.ncbi.nlm.nih.gov/nuccore/60549163. Accessed 13 January 2009
6. Current progress on development of respiratory syncytial virus vaccine. Chang J, BMB Rep 2011 44 232 237
7. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS, Vaccine 2013 31 209 B215
8. The future of respiratory syncytial virus vaccine development. Polack FP, Karron RA, Pediatr Infect Dis J 2004 23 65 S73
9. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J, Osterhaus AD, de Groot R, Corvaia N, Beck A, Bouveret-Le-Cam N, Bonnefoy JY, J Infect Dis 2001 184 1456 1460
10. Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate. Plotnicky H, Siegrist CA, Aubry JP, Bonnefoy JY, Corvaïa N, Nguyen TN, Power UF, Vaccine 2003 21 2651 2660
11. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Munoz FM, Piedra PA, Glezen WP, Vaccine 2003 21 3465 3467
12. Induction of balanced immunity in BALB/c mice by vaccination with a recombinant fusion protein containing a respiratory syncytial virus G protein fragment and a CTL epitope. Zeng RH, Gong W, Fan CF, Wang YF, Mei XG, Vaccine 2006 24 941 947
13. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA, J Infect Dis 1998 177 467 469
14. Co-immunization of BALB/c mice with recombinant immunogens containing G protein fragment and chimeric CTL epitope of respiratory syncytial virus induces enhanced cellular immunity and high level of antibody response. Fan CF, Mei XG, Vaccine 2005 23 4453 4461
15. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, O'Shea AF, Gruber WC, Murphy BR, Vaccine 2007 25 7372 7378
16. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. Luongo C, Winter CC, Collins PL, Buchholz UJ, J Virol 2012 86 10792 10804
17. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. Whitehead SS, Bukreyev A, Teng MN, Firestone CY, St Claire M, Elkins WR, Collins PL, Murphy BR, J Virol 1999 73 3438 3442
18. Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents. Jin H, Cheng X, Zhou HZ, Li S, Seddiqui A, J Virol 2000 74 74 82
19. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Widjojoatmodjo MN, Boes J, van Bers M, van Remmerden Y, Roholl PJ, Luytjes W, Virol J 2010 67 114 121
20. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH and M2-2 genes are attenuated in vitro and in vivo. Jin H, Zhou H, Cheng X, Tang R, Munoz M, Nquyen N, Virology 2000 273 210 218
21. Genetic variability of respiratory syncytial viruses (RSV) prevalent in Southwestern China from 2006 to 2009:emergence of subgroup B and A RSV as dominant strains. Zhang ZY, Du LN, Chen X, Zhao Y, Liu EM, Yang XQ, Zhao XD, J Clin Microbiol 2010 48 1201 1207
22. Human respiratory syncytial virus in children with acute respiratory tract infections in China. Zhang RF, Jin Y, Xie ZP, Liu N, Yan KL, Gao HC, Song JR, Yuan XH, Xiao NG, Guo MW, Zhou QH, Hou YD, Duan Z, J Clin Microbiol 2010 48 11 4193 4199
23. A stabilized respiratory syncytia virus reverse genetics system amenable to recombination-mediated mutagenesis. Hotard AL, Shaikh FY, Lee S, Yan D, Teng MN, Plemper RK, Crowe JE Jr, Moore ML, Virology 2012 434 129 136
24. Rescue of bovine respiratory syncytial virus from cloned cDNA:entire genome sequence of BRSV strain A51908. Yunus AS, Khattar SK, Collins PL, Samal SK, Virus Genes 2001 23 157 164
25. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. Lo MS, Brazas RM, Holtzman MJ, J Virol 2005 79 9315 9319
26. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Collins PL, Murphy BR, Proc Am Thorac Soc 2005 2 166 173
27. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro:clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS, Proc Natl Acad Sci 1997 94 13961 13966
28. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. Techaarpornkul S, Barretto N, Peeples ME, J Virol 2001 75 6825 6834
29. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5'proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR, Proc Natl Acad Sci U S A 1995 92 11563 11567
30. CD8+T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. Olson MR, Varga SM, J Immunol 2007 179 5415 5424
31. The number of respiratory syncytial virus (RSV)-specific memory CD8+T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. Olson MR, Hartwig SM, Varga SM, J Immunol 2008 181 7958 7968
32. Virus-specific CD8+T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. Srikiatkhachorn A, Braciale TJ, J Exp Med 1997 186 421 432
33. The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-Lymphocyte response despite lacking major histocompatibility complex class I-Restricted epitopes. Bukreyev A, Serra ME, Laham FR, Melendi GA, Kleeberger SR, Collins PL, Polack FP, J Virol 2006 80 5854 5861
34. Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma. Ostler T, Davidson W, Ehl S, Eur J Immunol 2002 32 2117 2123
35. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. Elliott MB, Pryharski KS, Yu Q, Boutilier LA, Campeol N, Melville K, Laughlin TS, Gupta CK, Lerch RA, Randolph VB, LaPierre NA, Dack KM, Hancock GE, J Virol 2004 78 8446 8454
36. The attachment(G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+T cell responses. Varga SM, Wissinger EL, Braciale TJ, J Immunol 2000 165 6487 6495
37. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS, J Virol 1998 72 2871 2880
38. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C, J Virol 1996 70 7783 7791
39. Immune responses to the nonglycosylated ectodomain of respiratory syncytial virus attachment glycoproteinmediate pulmonary eosinophilia in inbred strains of mice with different MHC haplotypes. Hancock GE, Tebbey PW, Scheuer CA, Pryharski KS, Heers KM, LaPierre NA, J Med Virol 2003 70 301 308
40. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. Johnson TR, Teng MN, Collins PL, Graham BS, J Virol 2004 78 6024 6032
41. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Johnson TR, Graham BS, Pediatr Infect Dis J 2004 23 46 S57
42. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Polack FP, Irusta PM, Hoffman SJ, Schiatti MP, Melendi GA, Delgado MF, Laham FR, Thumar B, Hendry RM, Melero JA, Karron RA, Collins PL, Kleeberger SR, Proc Natl Acad Sci U S A 2005 102 8996 9001